These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28335783)

  • 1. SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China.
    Li Y; Wang J; Wang J; Xiao Y; Xu B; Li H; Yang L; Hao X; Ma Y
    Virol J; 2017 Mar; 14(1):62. PubMed ID: 28335783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
    Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
    Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
    Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
    Bizid S; Bouali R; Ouedrani A; Mrabet A; Ben Abdallah H; Ghazouani E; Abdelli N
    Tunis Med; 2016 Jan; 94(1):6-11. PubMed ID: 27525598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.
    Liu T; Sha K; Yang L; Wang Y; Zhang L; Liu X; Yang F
    PLoS One; 2014; 9(3):e91316. PubMed ID: 24642705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
    BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Xu H; Guo LL; He LL; Chen Y; Liu K; Lei BJ; Lei XZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):855-9. PubMed ID: 23387213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
    Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
    Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
    Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C.
    Liang PC; Lin PC; Huang CI; Huang CF; Yeh ML; Zeng YS; Hsu WY; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chiou SS; Yu ML
    J Formos Med Assoc; 2018 Jan; 117(1):14-23. PubMed ID: 29097076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
    Halfon P; Bourliere M; Ouzan D; Maor Y; Renou C; Wartelle C; Pénaranda G; Tran A; Botta D; Oules V; Castellani P; Portal I; Argiro L; Dessein A
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):931-5. PubMed ID: 21900787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.